乐
乐观
乐观 · 25%PBM
$4.72
情景价格
$3.055
+0.119 (+3.91%)收盘时
Loading chart…
- 最高
- 3.140
- 开盘
- 3.020
- 成交量加权均价
- 3.05
- 成交量
- 24.52K
- 市值
- —
- 最低
- 2.950
- 成交额
- 74.75K
- 企业价值/息税折旧摊销前利润（TTM）
- 0.00
Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company specializing in neuroplastogen-based therapeutics and the manufacture of pharmaceutical-grade drug candidates. The Company is focused on developing nature-derived, non-synthetic psilocybin and ibogaine-based neuroplastogen medicine. The Company is engaged in addressing unmet mental health needs. It is also focused on an evidence-based approach to developing safe, effective and FDA-approved nature-derived neuroplastogen treatments across a range of mental health disorders.
AI 分析 of Psyence Biomedical Ltd (PBM)
持有Psyence Biomedical Ltd is not a good buy right now due to its current price of 3.06, which is significantly down 90.21% year-to-date. The RSI is at 28.64, indicating that the stock is oversold, but the forward P/E ratio is 0, suggesting a lack of earnings growth potential. The main risk is the company's high volatility, with a 52-week change of -96.83%.
估值指标
Psyence Biomedical Ltd（PBM）当前预期市盈率为 0.00，5 年平均预期市盈率为 0.00。
Alphio AI 对 PBM 的价格情景
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。
事件时间线
资讯
7.509-28NASDAQ.COMPsyence Biomedical Secures Exclusive Ibogaine Development Deal
8.509-23NASDAQ.COMPsyence BioMed Commits $5 Million to Support U.S. Ibogaine Program
8.509-14NASDAQ.COMPsyence Establishes Texas Ibogaine Research Corporation for U.S. Development
8.508-19NASDAQ.COMPsyence Biomedical Welcomes U.S. Support for Ibogaine Development
8.508-18NewsfilterPsyence BioMed Welcomes Trump's Support for Accelerated Ibogaine Development
PBM 常见问题 —— 由 Alphio AI 解答
Psyence Biomedical Ltd. is a vertically integrated biopharmaceutical company specializing in neuroplastogen-based therapeutics and the manufacture of pharmaceutical-grade drug candidates. The Company is focused on developing nature-derived, non-synthetic psilocybin and ibogaine-based neuroplastogen medicine. The Company is engaged in addressing unmet mental health needs. It is also focused on an evidence-based approach to developing safe, effective and FDA-approved nature-derived neuroplastogen treatments across a range of mental health disorders. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Psyence Biomedical Ltd is not a good buy right now due to its current price of 3.06, which is significantly down 90.21% year-to-date. The RSI is at 28.64, indicating that the stock is oversold, but the forward P/E ratio is 0, suggesting a lack of earnings growth potential. The main risk is the company's high volatility, with a 52-week change of -96.83%.
社区
更多 ↗暂无帖子
注册或登录后参与讨论相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。